Company intelligence / Profile preview

CAS Lamvac Biotech Co., Ltd.

Guangzhou, Guangdong Province, Chinacas-lamvac.com ↗

Ownership: Private
Development stage: Other

Overview

The company has developed Plasmodium immunotherapy which is currently in Phase II clinical trials for various cancers including liver cancer, ovarian cancer, and thyroid cancer. The therapy works by activating the immune system that has been inhibited by cancer cells, counteracting tumor immunosuppressive microenvironment, inhibiting tumor angiogenesis, and inhibiting tumor growth and metastasis.

Therapeutic areas: Oncology
Modalities: Therapeutic vaccinesRecombinant plasmodium-based immunotherapy
Industry: Biotech

Drug pipeline

2 assets

plasmodium immunotherapy

Unknown

1 more asset in the full pipeline.

Partnerships

Guangzhou Institute of Biomedicine and Health (GIBH)

Beyond the preview

Go deeper on CAS Lamvac Biotech Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAS Lamvac Biotech Co., Ltd..